B-Cell Malignant Neoplasm clinical trials
9 active trials name this condition. Describe your situation to see which ones you may be eligible for.
By location
- A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
- A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
- A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
- UBX-303061 in Subjects With Relapsed/Refractory B-Cell Malignancies
- A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
- A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
- AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
- Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
Guides for people searching for a trial
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.
Showing active trials that list “B-Cell Malignant Neoplasm” as a condition. Eligibility shown on each trial is an estimate — the trial's study team makes the final decision.